← Leaderboards
Robert J Levy
Children'S Hosp Of Philadelphia
$36,673,646
Attributed
$47,904,986
Total exposure
16
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.4M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$61,621,363 · 16
FDA$5,450,256 · 1
By mechanism
P50$27,659,715 · 3
R01$24,468,620 · 9
T32$12,638,940 · 1
P20$1,308,585 · 1
R21$456,515 · 1
R56$420,000 · 1
Top collaborators
- Giovanni Ferrari16 shared
- Joseph W Rossano9 shared
- Ilia Fishbein5 shared
- Robert E Shaddy4 shared
Most similar at Children'S Hosp Of Philadelphia
Same institution · by research overlap
- Giovanni Ferrari$11,594,575
- Ilia Fishbein$3,426,991
- Stanley Joseph Stachelek$1,791,630
Others in their field
Top investigators on “In Vitro”
- David Heimbrook · Leidos Biomedical Research, Inc.$553,787,942
- Leonard Freedman · Leidos Biomedical Research, Inc.$310,441,779
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,686,873
- Dennis R. Burton · Scripps Research Institute$79,204,175
Research focus
In VitroCalcificationFeasibility StudiesAffectIn VivoProgramsMediatingInvestigationSheepTrainingExtracellular MatrixBaseMolecularHeart ValvesCellsOperative Surgical ProceduresImplantRepairedBiomechanicsGene ExpressionTissue /Cell CultureMitral ValveFunctional DisorderPharmaceutical Preparations
Grant awards (93)
Serotonin Signaling in Mitral Valve Homeostasis, Maintenance and Restoration$790,183
R01 · FY2025 · HL · contact PI
Mitigation Strategies for Metabolic Syndrome-induced Bioprosthetic Heart Valve Degeneration$764,402
R01 · FY2025 · HL
Training in Molecular Therapeutics for Pediatric Cardiology$572,809
T32 · FY2025 · HL · contact PI
Training in Molecular Therapeutics for Pediatric Cardiology$809,669
T32 · FY2024 · HL · contact PI
Mitigation Strategies for Metabolic Syndrome-induced Bioprosthetic Heart Valve Degeneration$780,527
R01 · FY2024 · HL
Serotonin Signaling in Mitral Valve Homeostasis, Maintenance and Restoration$697,910
R01 · FY2024 · HL · contact PI
Serotonin Signaling in Mitral Valve Homeostasis, Maintenance and Restoration$721,824
R01 · FY2023 · HL · contact PI
Supplement to Serotonin Signaling in Mitral Valve Homeostasis, Maintenance and Restoration$594,951
R01 · FY2023 · HL · contact PI
Training in Molecular Therapeutics for Pediatric Cardiology$464,893
T32 · FY2023 · HL · contact PI
Medical Device Consortium at the Children's Hospital of Philadelphia$999,999
P50 · FY2022 · FD · contact PI
Serotonin Signaling in Mitral Valve Homeostasis, Maintenance and Restoration$731,206
R01 · FY2022 · HL · contact PI
Training in Molecular Therapeutics for Pediatric Cardiology$498,557
T32 · FY2022 · HL · contact PI
Medical Device Consortium at the Children's Hospital of Philadelphia$150,000
P50 · FY2022 · FD · contact PI
Medical Device Consortium at the Children's Hospital of Philadelphia$999,999
P50 · FY2021 · FD · contact PI
Serotonin Signaling in Mitral Valve Homeostasis, Maintenance and Restoration$791,513
R01 · FY2021 · HL · contact PI
Oxidation-mediated structural degeneration of bioprosthetic heart valves$765,816
R01 · FY2021 · HL · contact PI
Training in Molecular Therapeutics for Pediatric Cardiology$693,983
T32 · FY2021 · HL · contact PI
Medical Device Consortium at the Children's Hospital of Philadelphia$150,000
P50 · FY2021 · FD · contact PI
Medical Device Consortium at the Children's Hospital of Philadelphia$999,999
P50 · FY2020 · FD · contact PI
Oxidation Resistant ApoA1 Gene Delivery Stents$823,802
R01 · FY2020 · HL · contact PI
Oxidation-mediated structural degeneration of bioprosthetic heart valves$785,792
R01 · FY2020 · HL · contact PI
Training in Molecular Therapeutics for Pediatric Cardiology$683,329
T32 · FY2020 · HL · contact PI
Medical Device Consortium at the Children's Hospital of Philadelphia$150,270
P50 · FY2020 · FD · contact PI
Medical Device Consortium at the Children's Hospital of Philadelphia$999,997
P50 · FY2019 · FD · contact PI
Oxidation Resistant ApoA1 Gene Delivery Stents$828,102
R01 · FY2019 · HL · contact PI
Oxidation-mediated structural degeneration of bioprosthetic heart valves$809,825
R01 · FY2019 · HL · contact PI
Training in Molecular Therapeutics for Pediatric Cardiology$648,990
T32 · FY2019 · HL · contact PI
Serotonin Signaling in Mitral Valve Homeostasis, Maintenance and Restoration$648,985
R01 · FY2019 · HL · contact PI
Medical Device Consortium at the Children's Hospital of Philadelphia$999,992
P50 · FY2018 · FD · contact PI
Oxidation-mediated structural degeneration of bioprosthetic heart valves$846,165
R01 · FY2018 · HL · contact PI
Oxidation Resistant ApoA1 Gene Delivery Stents$832,402
R01 · FY2018 · HL · contact PI
Serotonin Signaling in Mitral Valve Homeostasis, Maintenance and Restoration$657,068
R01 · FY2018 · HL · contact PI
Training in Molecular Therapeutics for Pediatric Cardiology$261,744
T32 · FY2018 · HL · contact PI
Oxidation Resistant ApoA1 Gene Delivery Stents$853,842
R01 · FY2017 · HL · contact PI
Serotonin Signaling in Mitral Valve Homeostasis, Maintenance and Restoration$664,532
R01 · FY2017 · HL · contact PI
Training in Molecular Therapeutics for Pediatric Cardiology$634,042
T32 · FY2017 · HL · contact PI
Training in Molecular Therapeutics for Pediatric Cardiology$3,181
T32 · FY2017 · HL · contact PI
Serotonin Signaling in Mitral Valve Homeostasis, Maintenance and Restoration$700,532
R01 · FY2016 · HL · contact PI
Training in Molecular Therapeutics for Pediatric Cardiology$579,453
T32 · FY2016 · HL · contact PI
Training in Molecular Therapeutics for Pediatric Cardiology$594,687
T32 · FY2015 · HL · contact PI
Gene Delivery Stents AAV Formulations$420,000
R56 · FY2015 · HL · contact PI
Training in Molecular Therapeutics for Pediatric Cardiology$507,965
T32 · FY2014 · HL · contact PI
Training in Molecular Therapeutics for Pediatric Cardiology$401,291
T32 · FY2013 · HL · contact PI
Gene Delivery Stents$397,567
R01 · FY2013 · HL · contact PI
Training in Molecular Therapeutics for Pediatric Cardiology$429,510
T32 · FY2012 · HL · contact PI
Gene Delivery Stents$408,217
R01 · FY2012 · HL · contact PI
High Field Gradient Targeting Magnetic Nanoparticle Loaded Cells to Stents$205,265
R21 · FY2012 · HL · contact PI
TGA-ethanol Pretreated Bovine Pericardium for the Norwood Procedure$655,081
P20 · FY2011 · HL · contact PI
Training in Molecular Therapeutics for Pediatric Cardiology$511,307
T32 · FY2011 · HL · contact PI
Gene Delivery Stents$403,126
R01 · FY2011 · HL · contact PI
High Field Gradient Targeting Magnetic Nanoparticle Loaded Cells to Stents$251,250
R21 · FY2011 · HL · contact PI
TGA-ethanol Pretreated Bovine Pericardium for the Norwood Procedure$653,504
P20 · FY2010 · HL · contact PI
Training in Molecular Therapeutics for Pediatric Cardiology$503,258
T32 · FY2010 · HL · contact PI
Blood Outgrowth Endothelial Cell Seeding of Heart Valve Leaflets$477,697
R01 · FY2010 · HL · contact PI
Gene Delivery Stents$390,657
R01 · FY2010 · HL · contact PI
Training in Molecular Therapeutics for Pediatric Cardiology$499,280
T32 · FY2009 · HL · contact PI
Blood Outgrowth Endothelial Cell Seeding of Heart Valve Leaflets$480,552
R01 · FY2009 · HL · contact PI
Gene Delivery Stents$405,509
R01 · FY2009 · HL · contact PI
Genetic Mechanisms in Pediatric Heart Disease$3,714,502
P50 · FY2008 · HL · contact PI
Biocompatible Heterograft Biomaterials$602,521
P50 · FY2008 · HL · contact PI
Training in Molecular Therapeutics for Ped.Cardiology$428,643
T32 · FY2008 · HL · contact PI
Genetic Mechanisms in Pediatric Heart Disease$3,845,641
P50 · FY2007 · HL · contact PI
Biocompatible Heterograft Biomaterials$622,376
P50 · FY2007 · HL · contact PI
Training in Molecular Therapeutics for Ped.Cardiology$455,270
T32 · FY2007 · HL · contact PI
Genetic Mechanisms in Pediatric Heart Disease$3,860,779
P50 · FY2006 · HL · contact PI
Biocompatible Heterograft Biomaterials$608,878
P50 · FY2006 · HL · contact PI
Gene Delivery Stents$468,009
R01 · FY2006 · HL · contact PI
Training in Molecular Therapeutics for Ped.Cardiology$371,843
T32 · FY2006 · HL · contact PI
Genetic Mechanisms in Pediatric Heart Disease$3,854,258
P50 · FY2005 · HL
Biocompatible Heterograft Biomaterials$594,411
P50 · FY2005 · HL
Training in Molecular Therapeutics for Ped.Cardiology$476,737
T32 · FY2005 · HL
Gene Delivery Stents$468,525
R01 · FY2005 · HL
Genetic Mechanisms in Pediatric Heart Disease$3,891,453
P50 · FY2004 · HL
Biocompatible Heterograft Biomaterials$614,640
P50 · FY2004 · HL
Gene Delivery Stents$458,090
R01 · FY2004 · HL
Polyurethane Calcification:Mechanism and Inhibition$443,537
R01 · FY2004 · HL
Training in Molecular Therapeutics for Ped.Cardiology$412,214
T32 · FY2004 · HL
Gene Delivery Stents$483,187
R01 · FY2003 · HL
Polyurethane Calcification:Mechanism and Inhibition$430,618
R01 · FY2003 · HL
Cardiovascular Calcification Pathophysiology &Treatment$318,547
R01 · FY2003 · HL
TRAINING IN MOLECULAR THERAPEUTICS FOR PEDIATRIC CARDIOL$233,023
T32 · FY2003 · HL
CARDIOVASCULAR CALCIFICATION PATHOPHYSIOLOGY &TREATMENT$514,477
R01 · FY2002 · HL
Polyurethane Calcification:Mechanism and Inhibition$418,074
R01 · FY2002 · HL
TRAINING IN MOLECULAR THERAPEUTICS FOR PEDIATRIC CARDIOL$351,660
T32 · FY2002 · HL
CARDIOVASCULAR CALCIFICATION PATHOPHYSIOLOGY &TREATMENT$499,492
R01 · FY2001 · HL
Polyurethane Calcification:Mechanism and Inhibition$423,395
R01 · FY2001 · HL
TRAINING IN MOLECULAR THERAPEUTICS FOR PEDIATRIC CARDIOL$322,863
T32 · FY2001 · HL
MYOCARDIAL CONTROLLED RELEASE IMPLANTS FOR ARRHYTHMIAS$307,746
R01 · FY2001 · HL
CARDIOVASCULAR CALCIFICATION PATHOPHYSIOLOGY &TREATMENT$484,948
R01 · FY2000 · HL
POLYURETHANE CALCIFICATION, MECHANISM AND INHIBITION$395,569
R01 · FY2000 · HL
MYOCARDIAL CONTROLLED RELEASE IMPLANTS FOR ARRHYTHMIAS$301,702
R01 · FY2000 · HL
TRAINING IN MOLECULAR THERAPEUTICS FOR PEDIATRIC CARDIOL$288,739
T32 · FY2000 · HL
ANTIBODY DELIVERY OF GENE VASCULAR GRAFTS$119,244
R41 · FY2000 · HL